Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 13/20 | 0.40 |
| ▸ | EGFR | P00533 | 7/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262301 | 0.89 | ERBB2 (0.52) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL12310644 | 0.89 | ERBB2 (0.47) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL14773095 | 0.82 | BACE1 (0.42) | EGFRBTKMETKDR | |
| SCHEMBL13857447 | 0.75 | ERBB2 (0.47) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL12262304 | 0.75 | ERBB2 (0.54) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL12510766 | 0.73 | BACE1 (0.43) | EGFRBTKMETKDR | |
| SCHEMBL23308002 | 0.72 | TYK2 (0.39) | ERBB2EGFRALOX15SMN1; SMN2BTK | |
| SCHEMBL12322295 | 0.72 | EGFR (0.57) | ERBB2EGFRLCK | |
| SCHEMBL12310628 | 0.72 | BACE1 (0.45) | EGFRMETKDR | |
| SCHEMBL691621 | 0.72 | EGFR (0.43) | ERBB2EGFRAURKARPS6KB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ERBB2 918/4885EGFR 1981/4885LCK 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.